Assess Neo-Epitope Immunogenicity with NeoScreen® New Year Promotion

NeoScreen® from Immunitrack is the only platform in the world that offers high throughput MHC/epitope stability measurements. Until 28th February 2020, we are offering reduced pricing on for neo-epitope studies using our NeoScreen® services.

Accurate assessment of cancer mutations that elicit an immune response (so called neo-epitopes) is critical for the development of precision immunotherapy with increased safety and efficacy, e.g., to predict responders to checkpoint inhibitor therapy.1 Which neo-epitope(s) trigger a desired immune response? Which neo-epitope(s) combined with patient MHC variants can and should be produced for immune monitoring during checkpoint inhibitor therapy? Such questions are critical for ongoing clinical trials within cancer immunotherapy.

Traditionally, affinity of the MHC/epitope interaction has been used to predict immunogenicity, and the gold standard in silico prediction tool in this field is built upon affinity data. However, accumulating research data strongly suggests that stability of the MHC/epitope interaction is a superior predictor of epitope immunogenicity over affinity or in silico prediction methods based on affinity measurements alone.

If you are working in the fields of immune-oncology, vaccine design, or biologics, and want to know how NeoScreen® could improve your workflow and data quality, please get in touch with us for an informal chat. You can also read more about NeoScreen® on our website here ▸, or you can download a brochure with details on the promotion here ▸.

Note that the New Year promotion only applies to neo-epitope studies and is offered only to customers located in North America and Europe.

For further information, please contact:
Stephan Thorgrimsen, CEO
sthor@immunitrack.com

NeoScreen Neo-epitope Campaign 2020

References

  1. Smith, K.N. et al. Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. J Immunother Cancer20197(1):40.